A5084151718- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Cancer, Lipids, and Metabolism
- Hormonal and reproductive studies
- Cancer Research and Treatments
- Heat shock proteins research
- Renal cell carcinoma treatment
- Estrogen and related hormone effects
- Immune cells in cancer
- Clusterin in disease pathology
- CAR-T cell therapy research
- Ubiquitin and proteasome pathways
- Radiopharmaceutical Chemistry and Applications
- Urinary and Genital Oncology Studies
- Renal and related cancers
- S100 Proteins and Annexins
- Immune Cell Function and Interaction
- Hematopoietic Stem Cell Transplantation
- Redox biology and oxidative stress
- Urologic and reproductive health conditions
- Axon Guidance and Neuronal Signaling
- Epigenetics and DNA Methylation
Kyushu University
2014-2023
Konan Kosei Hospital
2023
Kyushu University Hospital
2020
Nagoya City University
2019
Vancouver General Hospital
2017-2018
University of Occupational and Environmental Health Japan
2016
Jikei University School of Medicine
2016
University of British Columbia
2012-2015
Iowa City Public Library
2015
BC Cancer Agency
2013
Defining the mechanisms underlying metastatic progression of prostate cancer may lead to insights into how decrease morbidity and mortality in this disease. An important determinant metastasis is epithelial-to-mesenchymal transition (EMT), that control process EMT cells are still emerging. Here, we report molecular chaperone Hsp27 (HSPB1) drives cancer, whereas its attenuation reverses decreases cell migration, invasion, matrix metalloproteinase activity. Mechanistically, silencing decreased...
Abstract TGF-β promotes epithelial–mesenchymal transition (EMT) and induces clusterin (CLU) expression, linking these genes to cancer metastasis. CLU is a pleiotropic molecular chaperone that confers survival proliferative advantage cells. However, the mechanisms by which regulates expression affects metastasis remain unknown. In this study, we report transcription factor Twist1 mediates TGF-β–induced expression. By binding E-boxes in distal promoter region of gene, regulated basal...
To evaluate the detailed immunosuppressive role(s) of PD-L2 given that its remains unclear in PD-1 signal blockade therapy animal models and humans.We generated mouse cell lines harboring various status PD-L1/PD-L2 evaluated tumor growth phenotypes tumor-infiltrated lymphocytes using several blockades models. In humans, correlation between immune-related gene expression CD274 (encoding PD-L1) or PDCD1LG2 PD-L2) was investigated The Cancer Genome Atlas (TCGA) datasets. addition, PD-L1 cells...
Research Article18 January 2018Open Access Source DataTransparent process SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1 James W Peacock Vancouver Prostate Centre, Vancouver, BC, Canada Department of Urologic Sciences, University British Columbia, Search for more papers this author Ario Takeuchi Urology, Graduate School Medical Kyushi University, Fukuoka, Japan Norihiro Hayashi The Jikei Medicine, Tokyo, Liangliang Liu Kevin J Tam Nader Al...
We determined whether intravesical recurrence is affected by inhibition of androgen signaling among men with nonmuscle invasive bladder cancer.We examined the rate treated or without suppression therapy deprivation for prostate cancer 5α-reductase inhibitor dutasteride benign prostatic hyperplasia.We studied 228 men, including 32 and 196 therapy. During a median followup 3.6 3.0 years developed in 4 (12.5%) 59 (30.1%) therapy, respectively. On multivariate analysis multiple tumors (HR 1.82,...
Intravesical inoculation of Mycobacterium bovis bacillus Calmette-Guérin (BCG) has been used for the treatment bladder cancer. Recent studies implied requirement neutrophil infiltration antitumor effect. In this study, we found that IL-17 was produced in after BCG treatment, preceding neutrophils. Neutrophils were reduced IL-17-deficient mice, which BCG-induced effect against intravesically inoculated cancer abolished. Notably, level production and number neutrophils BCG-treated γδ...
There are several reports of androgen receptor in bladder cancer cases but expression and the function androgen/androgen signaling remain unclear. We investigated role cancer.We evaluated AR mRNA tissue by quantitative real-time polymerase chain reaction. The cell growth drug sensitivity was also vitro vivo lines.AR inversely correlated with grade, stage spread. Of lines UMUC3 MBT-2 markedly expressed transcript protein. In each line blockade using deprivation, knockdown antiandrogen agents...
The androgen receptor (AR) is well known to play a central role in the pathogenesis of prostate cancer (PCa). In several studies, AR was overexpressed castration-resistant PCa (CRPC). However, mechanism overexpression CRPC not fully elucidated. Y-box binding protein-1 (YB-1) pleiotropic transcription factor that upregulated CPRC. We aimed elucidate YB-1 castration resistance and identify therapeutic potential targeting YB-1. Using immunohistochemistry, we found nuclear expression...
Background:Although androgen deprivation therapy for advanced prostate cancer initially exerts excellent anticancer effects, most treated with eventually recurs as castration-resistant (CRPC). Although aberrant kinase activation has been proposed a mechanism of castration resistance, comprehensive profiles in CRPC remain unknown. Therefore, we aimed to elucidate the kinome well role key molecules.
Prostate cancer progression from androgen dependence to castration resistance results at least in part oxidative stress induced by deprivation therapy. We elucidated the state and role of therapy possibility antioxidant human prostate cancer.We investigated 4-HNE (4-hydroxy-2-nonenal histidine adduct) staining, Twist1, YB-1 receptor expression immunohistochemistry samples treated with or without neoadjuvant Intracellular reactive oxygen species protein were examined CM-H(2)DCFDA Western blot...
Abstract BACKGROUND Taxanes, including docetaxel, are currently the only cytotoxic chemotherapeutic agents proven to confer survival benefit in patients with castration‐resistant prostate cancer (CRPC). However, merits of taxanes remain modest, and efforts needed improve their therapeutic efficacy. METHODS We evaluated sensitivity cells various using cytotoxicity assays. Gene protein expression levels were by quantitative real‐time polymerase chain reaction Western blotting analysis,...
// Masaki Shiota 1 , Akira Yokomizo Ario Takeuchi Kenjiro Imada Keijiro Kiyoshima Junichi Inokuchi Katsunori Tatsugami Saiji Ohga 2 Katsumasa Nakamura Hiroshi Honda and Seiji Naito Department of Urology, Graduate School Medical Sciences, Kyushu University, Fukuoka, Japan Clinical Radiology, Correspondence to: Yokomizo, email: Keywords : androgen-deprivation therapy, bladder cancer, prostate radical prostatectomy, radiotherapy Received January 21, 2015 Accepted March 03, Published April 14,...
The progression of prostate cancer to metastatic and castration-resistant disease represents a critical step. We previously showed that the transcription factor Twist1, which promotes epithelial-mesenchymal transition, was involved in progression. Similarly, protein kinase C (PKC) has been implicated both castration resistance cancer.In this study, we aimed elucidate role PKC/Twist1 signaling resistance, apply information development novel therapeutic concept using PKC inhibitor Ro31-8220...
Abstract Prostate cancer (PCa) is among the most commonly-occurring cancers worldwide and a leader in cancer-related deaths. Local non-invasive PCa highly treatable but limited treatment options exist for those with locally-advanced metastatic forms of disease underscoring need to identify mechanisms mediating progression. The semaphorins are large grouping membrane-associated or secreted signalling proteins whose normal roles reside embryogenesis neuronal development. In this context, help...
Incurable castration-resistant prostate cancer (CRPC) is driven by androgen receptor (AR) activation. Potent therapies that prevent AR signaling, such as Enzalutamide (ENZ), are mainstay treatments for CRPC; however patients eventually progress with ENZ resistant (ENZR) disease. In this study, we investigated one mechanism of resistance, and tried to improve therapeutic efficiency ENZ. We found HER2 expression increased in ENZR tumors cell lines, induced treatment LNCaP cells. ENZ-induced...
Although invasive and metastatic progression via the epithelial-mesenchymal transition (EMT) acquisition of resistance to castration are both critical steps in prostate cancer, molecular mechanism this interaction remains unclear. In study, we aimed elucidate signaling between EMT, apply information development a novel therapeutic concept using transforming growth factor-β (TGF-β) inhibitor SB525334 combined with androgen-deprivation therapy against cancer an vivo model. This study revealed...
Chemopreventive and potential therapeutic effects of soy isoflavones have been shown to be effective in numerous preclinical studies as well clinical prostate cancer. Although the inhibition androgen receptor signaling has supposed one mechanism underlying their effects, precise remains unclear. Thus, this study aimed clarify mechanism. Among isoflavones, equol suppressed prostate‐specific antigen expression most potently androgen‐dependent LNC aP cells. However, inhibitory effect on...
Abstract BACKGROUND Statins (3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase inhibitors) are cholesterol‐lowering drugs that widely used to prevent and treat atherosclerotic cardiovascular disease. Recent epidemiological studies suggest statins reduce serum prostate‐specific antigen (PSA) levels decrease the risk of prostate cancer. In present study, we determined molecular mechanisms related regulation PSA, androgen receptor (AR) cell proliferation in cancer lines by statins. METHODS...
Background and Objective To examine the association between features of metabolic syndrome (MetS) (obesity, hypertension, diabetes mellitus, dyslipidemia) risk biochemical recurrence (BCR) after radical prostatectomy in patients with prostate cancer. Methods This study included 283 Japanese localized cancer who were treated 2008 2012. Their oncological outcomes prognostic significance several clinicopathological factors, as well MetS, analyzed. Results Of men underwent prostatectomy, 49...
Although immune-related adverse events (irAEs) of treatment with immune-checkpoint inhibitors may be due to cellular immunity mediated by T lymphocytes, their pathogenesis has remained unknown. Here we collected bronchoalveolar lavage fluid (BALF) from a cancer patient nivolumab-induced pneumonitis and isolated mononuclear cells for next-generation sequencing the complementarity-determining region cell receptor (TCR) β chain. Mononuclear in peritumoral pleural effusion were similarly...